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Objectives: Some large population-based studies have reported a dose-related increased 
risk of cataracts and glaucoma associated with use of inhaled corticosteroids (ICS) in patients 
with asthma or chronic obstructive pulmonary disease (COPD). We evaluated the association 
between use of ICS-containing products, specifically fluticasone propionate/salmeterol fixed-dose 
  combination (FSC), and incidence of cataracts and glaucoma among patients with COPD in a 
large electronic medical record database in the United Kingdom.
Methods: We identified a cohort of patients aged 45 years and over with COPD in the General 
Practice Research Database (GPRD) between 2003 and 2006. Cases of incident cataracts or 
glaucoma were defined based on diagnosis and procedure codes and matched to controls from 
the risk set to estimate odds ratios (OR) and 95% confidence intervals (CI). The association with 
FSC or ICS exposure was modeled using conditional logistic regression. Medication exposure 
was assessed with respect to recency, duration, and number of prescriptions prior to the index 
date. Average daily dose was defined as none, low (1–250 mcg), medium (251–500 mcg), high 
(501–1000 mcg), or very high (1001+ mcg) using fluticasone propionate (FP) equivalents.
Results: We identified 2941 incident cataract cases and 327 incident glaucoma cases in the 
COPD cohort (n = 53,191). FSC or ICS prescriptions were not associated with risk of incident 
cataracts or glaucoma for any exposure category, after adjusting for confounders. We observed 
a lack of a dose response in all analyses, where low dose was the reference group. The odds 
of cataracts associated with FSC dose were medium OR: 1.1 (95% CI: 0.9–1.4); high OR: 1.2 
(95% CI: 0.9–1.5); and very high OR: 1.2 (95% CI: 0.9–1.7). The odds of glaucoma associated 
with FSC dose: medium OR: 1.0 (95% CI: 0.5–2.1); high OR: 1.0 (95% CI: 0.5–2.0); and very 
high OR: 1.0 (95% CI: 0.4–2.8).
Conclusions: FSC or other ICS exposure was not associated with an increased odds of cataracts 
or glaucoma, nor was a dose–response relationship observed in this population-based nested 
case-control study of COPD patients in the United Kingdom.
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Introduction
Inhaled corticosteroids (ICS) have been established as first-line therapy for the 
  management of moderate to severe asthma due to their favorable benefit to risk   profile 
and the low systemic absorption of corticosteroids via topical application to the lung. 
Over the past 25 years, the number of community prescriptions   administered for International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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ICS has increased substantially in the United Kingdom.1,2 
These medications are typically added to long-acting 
bronchodilators, and their use is often a marker of chronic 
obstructive pulmonary disease (COPD) severity. Patients 
treated with ICS have demonstrated improvements in 
baseline lung function, reduction in chronic symptoms and 
exacerbations, and improvements in quality of life.3
Despite the known benefits of corticosteroids for approved 
indications, oral corticosteroid (OCS) use has been associated 
with increased intraocular pressure, open angle glaucoma, 
and cataracts in the published literature. Corticosteroids are 
believed to increase resistance to aqueous humor outflow in 
the eye potentially increasing intraocular pressure.4,5 More-
over, these medications may increase the rate of opacification 
of the crystalline lens leading to accelerated formation of 
cataracts. Ophthalmic glucocorticoids have been associated 
with cataract formation as well as increased intraocular pres-
sure or glaucoma; however, studies on the effect of ICS show 
inconsistent effect estimates in the published literature.
Two large population-based studies examined the 
  association between ICS use and increased intraocular 
  pressure or glaucoma. The Blue Mountain Eye Study (BMES) 
reported the odds of intraocular pressure or   glaucoma among 
patients aged at least 49 years old with a   family history of 
  glaucoma were 2.5 times higher among ICS users compared 
to nonusers. A dose–response relationship was observed, 
yet the precision of estimates was poor.6 A second study 
in a cohort of elderly patients using respiratory medication 
reported no association between current use of ICS, including 
high doses of ICS for at least 3 months, and incident ocular 
hypertension or glaucoma.7
No effect of ICS use on risk of cataracts was observed 
in four smaller studies of asthmatics.8–11 However, four 
large population-based case-control studies reported a 
dose–response relationship with increased odds of incident 
cataracts with increasing daily dose of ICS.12–15 In one 
large UK-based study, ICS use was associated with a 25% 
increase in odds of cataract with every increase of 1000 µg 
daily dose of beclomethasone dipropionate equivalencies 
relative to no ICS use.16 Considering subtypes of cataracts, 
posterior subcapsular cataracts appear to have the strongest 
association with ever long-term use of ICS.17
Studies to date assessing the association between ICS 
use and these ocular events demonstrate evidence of an 
  inconsistent, weak, or null association. The purpose of the 
current study is to quantify the relationship between use of 
fluticasone propionate/salmeterol fixed-dose combination 
(FSC) and other ICS and glaucoma and cataracts among 
patients with COPD in a large health care database. This study 
considers various time windows of ICS exposure, duration of 
exposure, as well as cumulative dose.
Methods
Data source
The General Practice Research Database (GPRD) contains 
computerized medical records from general practitioners 
(GPs) in the United Kingdom. The database provides 
  anonymized longitudinal data that centralizes informa-
tion from primary care physicians as well as specialist 
  referrals and hospital admissions. Information collected in 
this   database includes demographics, prescription details, 
clinical events, preventive care provided, specialist referrals, 
hospital admissions, and other major health outcomes. This 
database was previously used in descriptive epidemiologi-
cal studies of respiratory disease and has been described 
elsewhere.18–21
study design
We used a case-control design nested within a cohort of 
patients with COPD in the GPRD between the years 2003 
and 2006. Patients were included in the cohort if they were at 
least 45 years old, had at least 1 year of data in the database, 
did not have a diagnosis of cystic fibrosis or prevalent lung 
cancer, and had a diagnosis of COPD, chronic bronchitis, 
chronic obstructive airway disease, or emphysema. Oxford 
Medical Information System (OXMIS) and READ codes 
defining COPD have been previously validated.22
Cases
The first new case of the event of interest (cataract or glau-
coma) was ascertained during follow-up from OXMIS or 
READ codes. Patients with a history of cataract or glaucoma 
in the year prior to the COPD event were excluded, and 
patients were censored at the time of the first event during the 
follow-up. Cases of cataracts, ascertained from diagnosis and 
procedure codes, included all combined subtypes, since it was 
difficult to discern coding for site-specific analyses. Incident 
cases of glaucoma were ascertained from a glaucoma diagno-
sis, an increase in ocular pressure, or a relevant prescription 
for treatment of these symptoms recorded in GPRD.
Controls
Controls were selected from the risk set at the time in which 
an incident case of either cataracts or glaucoma occurred. 
This date was referred to as the ‘index date’. The risk set 
included those patients in the cohort who were at risk for International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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developing either end point, yet did not meet the database 
criteria for a case in the cohort at the time the case of cataract 
or glaucoma occurred. Cases were matched to controls up 
to a 1:2 ratio, respectively, on age within 2 years, gender, 
general practice, and number of years in the cohort prior to 
the ocular event.
exposure
Exposure to either FSC or other ICS medications was 
ascertained by reviewing the prescription history of the 
patient in the 1-year period preceding the case of glaucoma 
or cataract (or matched index date for controls). Exposure 
to these medications was classified according to ever use, 
recency of use, duration of use, and number of prescrip-
tions prescribed. Ever use was defined as having at least 
one prescription of the medication of interest in the 1-year 
exposure window and coded as yes or no. Recency of use 
was defined as the number of days from the date of the 
ocular event (or index date for controls) in which the last 
prescription for the medication of interest was prescribed. 
Duration of medication exposure was quantified by calcu-
lating the sum of the days supplied for each prescription 
of interest in the year preceding the event. Number of pre-
scriptions was defined as the sum of prescriptions for each 
medication of interest in the preceding 1-year exposure 
window. Finally, average daily dose was calculated for 
FSC and other ICS medications separately in the 12 months 
preceding the index date.
 
Dose of prescriptionD ayss upplied × ()
= ∑ 365 25 1 . i
n
Overall cumulative exposure to the medication of interest 
was converted into fluticasone propionate equivalents and 
divided by a 12-month time window to obtain the average 
daily dose.
Covariates
We considered several variables as potential   confounders 
of the association between FSC or other ICS use and 
  incident glaucoma or cataract among patients with COPD. 
  Information on age, gender, body mass index (BMI), 
smoking status, number of COPD visits, number of 
COPD   hospitalizations, comedications (statin use, oxygen 
use, nebulizer use, or OCS), comorbidities (depression, 
  diabetes, rheumatoid arthritis, or hypertension), and count 
of   antibiotic prescriptions was collected in the 1-year period 
prior to cohort entry.
statistical analysis
Two separate models were generated to estimate the effects 
of FSC/ICS use and cataract and glaucoma outcomes. Both 
crude and adjusted odds ratios (ORs) and 95% confidence 
intervals (CIs) estimating the association between FSC use or 
ICS use and incident cataract and glaucoma were estimated 
using conditional logistic regression models. These models 
allowed estimation of effect estimates while adjusting for 
the confounding structure imposed by matching. Covariates 
included in the model were those that were considered a 
priori to confound the association between FSC/ICS use 
and the outcome. ORs and their respective 95% CIs were 
also calculated within strata of age and OCS use. However, 
data were sparse in these strata, resulting in poor precision 
of these stratified effect estimates.
Recency of exposure, duration of exposure, and number of 
prescriptions prescribed were modeled as categorical   variables 
using quartiles from the frequency distribution in the controls 
of each variable with no use as the referent group. Average 
daily dose was modeled using four   categories with low dose 
as the referent group (low: 1–250 FP, medium: 251–500 FP, 
high: 501–1000 FP, and very high: 1001+ FP). These categories 
reflect dose ranges commonly used in clinical practice. We 
were able to detect an OR of 1.65 for glaucoma and 1.20 for 
cataracts with 80% power based on 273 glaucoma cases and 
2404 cataract cases with an exposure frequency of 16%.
Results
Descriptive statistics
Cohort
The cohort included 53,191 patients with COPD. We matched 
2404 of the 2941 cataract cases to 5621 controls by age, 
gender, general practice, and length of time in the cohort. 
The additional 537 cases had no suitable controls in the risk 
set, so these patients were excluded from the case control 
analyses. Patients with cataracts included in the analysis were 
older compared to excluded cases. Ninety-seven percent of 
included cases were above the age of 50 compared to 91% 
of the excluded cases.
Approximately 50% of the cases and controls were aged 
70 years or older when the cataract was detected. The distribu-
tion of BMI, smoking status, and comorbidities were similar 
across both groups (Table 1). Thirty-three percent of the cases 
used FSC in the year prior to the index date compared to 29% 
of the controls; other ICS use was similar between cases and 
controls (52% and 50%, respectively).
Of the 327 glaucoma cases, 273 were matched by age, 
gender, general practice, and length of time in the cohort to International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Table 1 Demographic characteristics of cases and controls by analysis
Cataract Glaucoma
Cases (N = 2404) Controls (N = 5621) Cases (N = 273) Controls (N = 703)
N  (%) N  (%) N  (%) N  (%)
Age at indexa
  45–49 0 0 2 (0.04) – – – –
  50–54 8 (0.3) 22 (0.4) 3 (1.1) 8 (1.1)
  55–59 54 (2.3) 129 (2.3) 9 (3.3) 20 (2.8)
  60–64 122 (5.1) 329 (5.9) 24 (8.8) 54 (7.7)
  65–69 284 (11.8) 781 (13.9) 44 (16.1) 126 (17.9)
  70–74 472 (19.6) 1220 (21.7) 61 (22.3) 159 (22.6)
  75–79 697 (29) 1674 (29.8) 66 (24.2) 179 (25.5)
  80–85 653 (27.2) 1274 (22.7) 54 (19.8) 138 (19.6)
 $ 86 114 (4.7) 190 (3.4) 12 (4.4) 19 (2.7)
gender
  Female 1235 (51.4) 2793 (49.7) 143 (52.4) 357 (50.8)
  Male 1169 (48.6) 2828 (50.3) 130 (47.6) 346 (49.2)
BMI
  Missing 1203 (50.0) 2958 (52.6) 138 (50.6) 366 (52.1)
  10–18.49 82 (3.4) 185 (3.3) 4 (1.5) 23 (3.3)
  18.50–24.99 435 (18.1) 963 (17.1) 56 (20.5) 111 (15.7)
  25–29.99 382 (15.9) 881 (15.7) 39 (14.3) 109 (15.5)
  30–70 302 (12.6) 634 (11.3) 36 (13.2) 94 (13.4)
smoking status
  nonsmoker 348 (14.5) 743 (13.2) 31 (11.4) 91 (12.9)
  ex-smoker 1112 (46.3) 2437 (43.4) 120 (44) 292 (41.5)
  smoker 493 (20.5) 1324 (23.6) 69 (25.3) 186 (26.5)
  Unknown 451 (18.8) 1117 (19.9) 53 (19.4) 134 (19.1)
Comorbid conditions
  Vertebral fracture 11 (0.5) 24 (0.4) 2 (0.7) 3 (0.4)
  Depression 120 (5) 228 (4.1) 12 (4.4) 38 (5.4)
  Diabetes 350 (14.6) 538 (9.6) 23 (8.4) 76 (10.8)
  rheumatoid arthritis 11 (0.5) 40 (0.7) 0 0 5 (0.7)
  Asthma 276 (11.5) 625 (11.1) 35 (12.8) 75 (10.7)
  Osteoporosis 53 (2.2) 112 (1.2) 7 (2.6) 11 (1.6)
  stroke 38 (1.6) 74 (1.3) 4 (1.5) 10 (1.4)
  Anemia 90 (3.7) 184 (3.3) 5 (1.8) 20 (2.8)
  Osteopenia 13 (0.5) 26 (0.5) 1 (0.4) 5 (0.7)
  Back pain 307 (12.8) 627 (11.2) 40 (14.7) 86 (12.2)
  Falls 137 (5.7) 247 (4.4) 14 (5.1) 31 (4.4)
  hyperparathyroid 4 (0.2) 4 (0.1) 0 0 1 (0.14)
  Dementia 9 (0.4) 28 (0.5) 2 (0.7) 7 (1.0)
  hypertension 364 (15.1) 946 (16.8) 47 (17.2) 115 (16.4)
  Dyslipidemia 114 (4.7) 243 (4.3) 15 (5.5) 20 (2.84)
  Obesity 306 (12.7) 639 (11.4) 36 (13.2) 95 (13.5)
Antibiotic: number of scripts in the previous year
  none 723 (30.1) 1907 (34) 83 (30.4) 245 (34.9)
 1 440 (18.3) 1257 (22.4) 63 (23.1) 154 (21.9)
 2 344 (114.3) 832 (14.8) 37 (13.6) 100 (14.2)
  3–4 434 (18.1) 876 (15.6) 41 (15.0) 125 (17.8)
  $5 463 (19.3) 749 (13.3) 49 (18) 79 (11.2)
number of COPD visits
  none 549 (22.9) 1366 (24.3) 75 (27.5) 185 (26.3)
 1 990 (41.2) 2385 (42.4) 104 (38.1) 277 (39.4)
 2 386 (16.1) 968 (17.2) 47 (17.2) 113 (16.1)
 3 + 479 (19.9) 902 (16.1) 47 (17.2) 128 (18.2)
number of COPD hospitalizations
  none 2189 (91.1) 5306 (94.4) 254 (93.0) 662 (94.2)
 1 167 (7) 252 (4.5) 15 (5.5) 33 (4.7)
 2 + 48 (2.0) 63 (1.1) 4 (1.5) 8 (1.1)
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703 controls. Excluded glaucoma cases (16.7%) were four 
times more likely to be between the ages of 44 and 49 years 
compared to cases included (4.4%) in the analysis. Smoking 
status appeared to be equally distributed between cases and 
controls; however, data were missing on smoking status of 
19% of the cases and controls. Approximately 50% of cases 
and controls were aged above 65, and 25% were smokers. 
FSC use in the year prior to the index date (29% and 32%) and 
prior use of an ICS-containing prescription (50% and 48%) 
were similar between cases and controls, respectively.
Multivariate models
Cataracts
We estimated the ORs and 95% CIs for the association 
between FSC or other ICS use and cataracts adjusting for 
potential confounding variables (COPD hospitalizations, 
BMI, smoking status, statin use, depression, diabetes, rheu-
matoid arthritis, hypertension, oxygen use, nebulizer use, 
and count of antibiotic prescriptions). Exposure to FSC and 
other ICS was categorized using multiple exposure criteria 
with the reference group being ‘no use in the year prior to 
the index date’ for all analyses.
The unadjusted odds of incident cataracts associated 
with ever use of ICS in the last year (2006) was 1.32 (95% 
CI: 1.18–1.47) relative to no ICS use in the last 12 months 
(Table 3). An increased odds (OR: 1.19; 95% CI: 1.08–1.32) 
of lesser magnitude was also observed for the unadjusted 
odds of cataracts among ever users of FSC in the last year 
(Table 2). The unadjusted odds of cataracts increased with 
number of prescriptions in the last year as well as duration of 
use compared to no use for users of both FSC and other ICS 
medications. However, no association between FSC or other 
ICS use and the odds of cataract after adjusting for potential 
confounding variables was observed.
There was no pattern of increased odds of cataracts associ-
ated with more recent use of FSC or other ICS. The only signifi-
cant association with increased odds for cataracts was observed 
for the exposure category of FSC prescription written between 
13 and 25 days prior to the index date relative to no FSC use in 
the last year (OR: 1.24; 95% CI: 1.01–1.51) (Table 2).
There was no pattern of increased odds for cataracts 
associated with duration of FSC or other ICS exposure. The 
odds for cataracts was increased for very long duration of 
exposure to other ICS (381+ days) compared to no other ICS 
use (OR: 1.22; 95% CI: 1.02–1.46) (Table 3). Similarly, there 
was no pattern of increased odds for cataracts associated with 
increasing number of prescriptions of either FSC or other 
ICS. A statistically significant association was observed for 
the highest frequency of prescription categories of either 
FSC (10+) (OR: 1.29; 95% CI: 1.05–1.59) or other ICS (9+) 
(OR: 1.22; 95% CI: 1.02–1.46) versus no FSC or no other 
ICS in the last year (Tables 2 and 3).
Table 1 (Continued)
Cataract Glaucoma
Cases (N = 2404) Controls (N = 5621) Cases (N = 273) Controls (N = 703)
N  (%) N  (%) N  (%) N  (%)
Comedications
  FsC 799 (33.2) 1655 (29.4) 78 (28.6) 226 (32.2)
  ICs-containing product 1823 (75.8) 3961 (70.5) 197 (72.2) 510 (72.6)
  BDP-containing product 847 (35.2) 1990 (35.4) 90 (33) 223 (31.7)
  BUD-containing product 350 (14.6) 663 (11.8) 43 (15.8) 95 (13.5)
  FP-containing product 898 (37.4) 1864 (33.2) 88 (32.2) 253 (36)
  Oral corticosteroids 1098 (45.7) 2128 (37.9) 119 (43.6) 264 (37.6)
  Antibiotic 1681 (69.9) 3714 (66.1) 190 (69.6) 458 (65.2)
  statin 850 (35.4) 1763 (31.4) 76 (27.8) 210 (29.9)
  nebulizer 476 (19.8) 761 (13.5) 51 (18.7) 92 (13.1)
  Other respiratory product 1369 (56.9) 2827 (50.3) 146 (53.5) 359 (51.1)
  Oxygen 160 (6.7) 268 (4.8) 15 (5.5) 45 (6.4)
  Tiotropium-only product 616 (25.6) 1224 (21.8) 57 (20.9) 164 (23.3)
  sABD-containing product 2156 (89.7) 4898 (87.1) 229 (83.9) 603 (85.8)
  sABD with ICs product 0 0 3 (0.1) nA nA nA nA
   ICs-containing product  
excluding FsC
1260 (52.4) 2799 (49.8) 136 (49.8) 338 (48.1)
Notes: Population includes patients with COPD in the gPrD between 2003 and 2006. Controls matched to cases on gender, age within 2 years, general practice, and 
number of years in the cohort prior to the event of interest. aIndex date is the date of the incident case of cataract or glaucoma and matched control.
Abbreviations:  BDP,  beclomethasone  dipropionate;  BMI,  body  mass  index;  BUD,  budesonide;  FSC,  fluticasone  propionate/salmeterol  fixed-close  combination;  FP, 
fluticasone propionate; GPRD, General Practice Research Data base; SABD, short-acting bronchodilator; NA, not applicable.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Table 2 Crude and adjusted Ors and 95% CIs for FsC use and incident cataracts between 2003 and 2006
FSC Crude OR 95% CI Adjusted OR 95% CI
ever use in the last year
  no use in the last year reference – reference –
  Use in the last year 1.19 (1.08–1.32) 1.1 (0.96–1.24)
Last use prior to index date (days)
  no use in the last year reference – reference –
  Last use prior 12 days 1.10 (0.92–1.33) 1.02 (0.83–1.27)
  Last use prior 13–25 days 1.38 (1.16–1.64) 1.24 (1.01–1.51)
  Last use prior 26–52 days 1.12 (0.94–1.34) 1.12 (0.91–1.38)
  Last use prior 53–365 days 1.17 (0.98–1.4) 1.06 (0.87–1.30)
Duration of use (days)
  no use in last year reference – reference –
  1–90 1.15 (0.96–1.37) 1.06 (0.87–1.29)
  91–180 1.14 (0.96–1.34) 1.05 (0.87–1.27)
  181–270 1.28 (1.04–1.57) 1.18 (0.93–1.49)
 $ 271 1.25 (1.05–1.49) 1.20 (0.97–1.48)
number of prescriptions
  no prescriptions in last year reference – reference –
  1–3 1.10 (0.92–1.31) 1.02 (0.84–1.24)
  4–6 1.12 (0.95–1.33) 1.07 (0.88–1.30)
  7–9 1.25 (1.02–1.53) 1.20 (0.95–1.52)
 $ 10 1.34 (1.13–1.59) 1.29 (1.05–1.59)
Notes: Population includes patients with COPD in the gPrD between 2003 and 2006. Controls matched to cases on gender, age within 2 years, general practice, and number 
of years in the cohort prior to the event of interest. Model adjusted for other inhaled corticosteroid use, asthma, long-acting beta agonists, short-acting bronchodilator, oral 
corticosteroid use, COPD hospitalizations, BMI, smoking status, statin use, depression, diabetes, rheumatoid arthritis, hypertension, oxygen use, nebulizer use, and count of 
antibiotic prescriptions.
Abbreviations: CI, confidence interval; FSC, fluticasone propionate/salmeterol fixed dose combination; GPRD, General Practice Research Database; OR, odds ratio.
Table 3 Crude and adjusted Or and 95% CI of the association between ICs use and incident cataracts between 2003 and 2006
ICS1 Crude OR 95% CI Adjusted OR 95% CI
ever use in the last year
  no use reference – reference –
  ever use 1.32 (1.18–1.47) 1.10 (0.97, 1.24)
Last use prior to index date (days)
  no use reference – reference –
  18 days 1.19 (1.03–1.37) 1.19 (1.00, 1.41)
  19–38 days 1.07 (0.91–1.25) 1.09 (0.90, 1.31)
  39–100 days 1.06 (0.91–1.23) 1.08 (0.90, 1.28)
  101–365 days 1.12 (0.97–1.3) 1.06 (0.90, 1.25)
Duration of use (days)
  no use in last year reference – reference –
  1–120 1.15 (0.99–1.33) 1.11 (0.94, 1.32)
  121–230 0.99 (0.85–1.15) 0.99 (0.83, 1.18)
  231–380 1.14 (0.98–1.32) 1.15 (0.97, 1.37)
  $381 1.17 (1.01–1.36) 1.22 (1.02, 1.46)
number of prescriptions
  no prescriptions in last year reference – reference –
  1–3 1.06 (0.93–1.22) 1.07 (0.92, 1.25)
  4–5 1.02 (0.87, 1.21) 1.02 (0.84, 1.23)
  6–8 1.10 (0.95–1.28) 1.14 (0.95, 1.36)
 $ 9 1.27 (1.09–1.48) 1.33 (1.10, 1.60)
Notes: Population includes patients with COPD in the gPrD between 2003 and 2006. Controls matched to cases on gender, age within 2 years, general practice, and 
number of years in the cohort prior to the event of interest. Models adjusted for FsC, asthma, long-acting beta agonists, short-acting bronchodilators – containing product, 
oral corticosteroids, COPD hospitalizations, BMI, smoking status, statin use, depression, diabetes, rheumatoid arthritis, hypertension, oxygen use, nebulizer use, and count 
of antibiotic prescriptions. 1ICs use excluding FsC.
Abbreviations: BMI, body mass index; CI, confidence interval; ICS, inhaled corticosteroids; GPRD, General Practice Research Database; OR, odds ratio.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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In the average daily dose analyses, no pattern of 
association between increasing levels of FSC or other ICS 
exposure and increased odds of cataracts was observed in 
the 12-month study period (Figure 1). Results were similar 
in the 3- and 6-month intervals prior to the index date (data 
not shown). Furthermore, the CIs for the FSC and other ICS 
estimates overlapped, suggesting no difference between the 
class-level and FSC-specific exposure odds estimates.
glaucoma
There was only one statistically significant unadjusted OR 
observed between FSC and other ICS use (Tables 4 and 5) 
with glaucoma in this population of COPD patients (last 
use in prior 39–100 days crude OR: 1.82; CI: 1.19–2.76). 
However, no adjusted ORs had 95% CIs, which excluded 
the null value and therefore provided no evidence of an 
increased risk for glaucoma associated with FSC or other 
ICS use. Moreover, no association was observed between 
average daily dose of FSC or ICS and incident glaucoma in 
the 12-month analysis (Figure 2) or 3- and 6-month analyses 
(not shown).
Discussion
The results of our analysis in a UK population-based COPD 
patient cohort were not consistent with an association 
between exposure to FSC or other ICS and increased risk of 
ocular events (cataracts or glaucoma).
Several observational studies have shown an   association 
between ICS use and increased risk of either cataracts or 
glaucoma, although the applicability of these studies to risks 
for COPD patients is limited. The previous studies were not 
specific to COPD patients who tend to be exposed to both 
ICS for routine management of their symptoms and OCS 
for managing acute exacerbations.7,12,14,15 Further, the sample 
sizes within strata of high average daily dose of ICS exposure 
or longer duration of ICS exposure were relatively small, 
leading to imprecise estimates with wide CIs.
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Figure 1 Association between 1 year prior FsC or ICs prescriptions and odds of 
cataracts: average daily dose analysis.
Notes: reference: low average daily dose.
Abreviations:  FsC,  fluticasone  propionate/salmeterol  fixed-close  combination; 
ICs, inhaled corticosteroids.
Table 4 Crude and adjusted Or and 95% CI of the association between FsC use and incident glaucoma between 2003 and 2006
FSC Crude OR 95% CI Adjusted OR 95% CI
ever use in the last year
  no use reference – reference –
  Use 0.84 (0.62–1.15) 0.68 (0.45–1.01)
Last use prior to index date (days)
  no use reference – reference –
  12 days 1.02 (0.61–1.71) 1.00 (0.53–1.89)
  13–25 days 0.92 (0.52–1.62) 0.67 (0.34–1.30)
  26–52 days 0.54 (0.3–0.97) 0.55 (0.28–1.09)
  53–365 days 0.98 (0.58–1.65) 0.81 (0.44–1.52)
Duration of use (days)
  no use reference – reference –
  1–90 1.14 (0.66–1.97) 1.02 (0.54–1.90)
  91–180 0.62 (0.36–1.08) 0.50 (0.26–0.96)
  181–270 0.68 (0.36–1.28) 0.52 (0.25–1.08)
 $ 271 0.99 (0.61–1.59) 0.75 (0.42–1.34)
number of prescriptions
  no prescriptions in last year reference – reference –
  1–3 1.14 (0.66–1.97) 1.01 (0.54–1.89)
  4–6 0.63 (0.36–1.10) 0.49 (0.26–0.93)
  7–9 0.70 (0.38–1.30) 0.50 (0.24–1.03)
 $ 10 0.96 (0.59–1.56) 0.72 (0.39–1.30)
Notes: Population includes patients with COPD in the gPrD between 2003 and 2006. Controls matched to cases on gender, age within 2 years, general practice, and 
number of years in the cohort prior to the event of interest. Model adjusted for other inhaled corticosteroids, asthma, long-acting beta agonists, short-acting bronchodilators, 
oral corticosteroids, BMI, smoking status, statin use, depression, diabetes, oxygen, nebulizer, and count of antibiotic prescriptions.
Abbreviations: BMI, body mass index; CI, confidence interval; FSC, fluticasone propionate/salmeterol fixed-dose combination; GPRD, General Practice Research Database 
Or, odds ratio.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Table 5 Crude and adjusted Or and 95% CI of the association between ICs use and incident glaucoma between 2003 and 2006
ICS Crude OR 95% CI Adjusted OR 95% CI
ever use in the last year
  no use reference – reference –
  Use 0.98 (0.72–1.34) 0.94 (0.64–1.38)
Last use prior to index date (days)
  no use reference – reference –
  18 days 1.18 (0.77–1.81) 1.07 (0.62–1.82)
  19–38 days 0.85 (0.53–1.35) 0.74 (0.41–1.34)
  39–100 days 1.82 (1.19–2.76) 1.82 (1.08–3.05)
  101–365 days 0.63 (0.38–1.04) 0.55 (0.31–0.99)
Duration of use (days)
  no use reference – reference –
  1–120 0.94 (0.6–1.47) 0.83 (0.49–1.43)
  121–230 0.99 (0.61–1.6) 0.78 (0.43–1.4)
  231–380 1.10 (0.71–1.68) 0.92 (0.53–1.58)
 $ 381 1.27 (0.83–1.94) 1.15 (0.68–1.95)
number of prescriptions
  none reference – reference –
  1–3 0.91 (0.59–1.39) 0.85 (0.51–1.41)
  4–5 1.29 (0.81–2.07) 1.17 (0.67–2.04)
  6–8 1.12 (0.72–1.75) 0.86 (0.49–1.52)
 $ 9 1.07 (0.69–1.66) 0.86 (0.49–1.49)
Notes: Population includes patients with COPD in the gPrD between 2003 and 2006. Controls matched to cases on gender, age within 2 years, general practice, and 
number of years in the cohort prior to the event of interest. Models Adjusted for FsC, asthma, long-acting beta agonists, short-acting bronchodilators, oral corticosteroids, 
BMI, smoking status, statin use, depression, diabetes, oxygen use, nebulizer use, and count of antibiotic prescriptions.
Abbreviations: BMI, body mass index; CI, confidence interval; FSC, fluticasene propionate/salmeterol fixed-close combination; GPRD, General Practice Research Database 
Or, odds ratio.
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Figure 2 Association between 1 year prior drug exposure and odds of glaucoma: 
average daily dose analysis.
Notes: reference: low average daily dose.
Abbreviation: ICs, inhaled corticosteroids.
Mitchell and colleagues reported an association between 
ICS use and glaucoma among patients with a family history 
of glaucoma or elevated intraocular pressure.6 However, 
these data were from a cross-sectional design, which does 
not allow for clear assessment of the temporality of the 
association, for example, that the exposure clearly preceded 
the event of interest. A dose–response relationship was 
reported, yet the 95% CIs for the estimates were wide; the 
OR for the highest dose ranged from 1.0 to 38.6. Further, 
Chylack and colleagues reported results from a randomized 
clinical trial of asthma patients comparing either 640 µg 
daily of ciclesonide to beclomethasone dipropionate. The 
mean change from baseline in LOCIII scores was small and 
did not differ from a normal aging population over 1 year.23 
The results from this randomized clinical study are consistent 
with our findings.
The many strengths of our GPRD study were method-
ological, including the nesting of the case-control study 
within a population-based cohort of patients with diagnosed 
COPD. The cohort included over 53,000 patients allowing 
for increased precision in the effect estimates. The sensitivity 
and specificity of both COPD diagnosis and outcomes coding 
were good in previous validation studies in the GPRD despite 
our inability to use a standardized method for ascertainment 
of glaucoma cases.22,24 Matching controls on age and sex are 
critical considering that they are the two strongest risk factors 
for the outcomes of interest. Matching on general practice 
serves as a proxy for both physician prescribing patterns and 
socioeconomic status of neighborhood. Multiple indicators of 
COPD severity were included in multivariate models in order 
to reduce the potential confounding by severity. Finally, the 
effect of FSC was modeled in a number of ways to charac-
terize exposure and explore the biologic plausibility of any 
observed increase in risk.
There were several limitations in this study. The first is the 
potential for confounding by severity/indication. If disease 
severity is associated with both the likelihood of receiving International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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the medication and the probability of the outcome, then 
good markers of disease severity are needed to adjust for this 
potential confounding. We did not have access to clinical 
parameters that could further characterize COPD severity. 
Information about other parameters linked to outcome risk, 
such as physical activity, functional status (performance 
of activities of daily living), community involvement, and 
assistance with ambulation, are also absent from electronic 
medical records and could not be adjusted for in multivariate 
models. However, we included the number of GP visits and 
hospitalizations as proxies for exacerbations, as well as num-
ber of antibiotic and OCS prescriptions. We also included 
comorbid conditions and medications in the multivariate 
logistic regression that were associated with exposure, as 
well as the outcomes of interest, to reduce confounding bias 
in the adjusted risk estimates.
There are limitations in measuring the exposure to OCS 
use, which is an important marker of disease   severity and 
a critical risk factor for the outcomes of interest. OCSs 
  administered in the emergency room or inpatient hospi-
tal stays are not always captured in the medical record. 
In   addition, we were limited to prescriptions recorded in 
the database during the study period. Lifetime exposure to 
OCS was not available in the database, but we assume that 
disease severity measured via the covariates included in the 
model (comorbid conditions, health care utilization, and 
medication use) in the period prior to index date has rea-
sonably adjusted for COPD severity. However, there is the 
possibility of residual confounding after the adjustment for 
other medication use; this potential confounding by severity 
would result in a bias away from the null.
Exposures longer than 12 months could not be addressed 
in this study, since creating categories with longer exposure 
yielded small sample sizes with very few events, such that the 
precision of the estimates was no longer informative. Thus, 
patients who used ICS medications and then discontinued for 
13 months or longer prior to the ocular event could have been 
misclassified as a nonuser. We would expect the effect of this 
potential misclassification to be nondifferential with respect 
to case status. Thus, our estimate may have been biased 
toward no association. Our study evaluated a shorter exposure 
history than that of Garbe and colleagues who assessed expo-
sure to ICS medications at 1–2 years and more than 2 years 
prior to the ocular event. However, Gonzalez et al assessed 
ICS use in the same exposure time window and reported a 
positive association between ICS use and ocular events, sug-
gesting that study of 12 months of exposure could detect an 
effect should one exist.7 Finally, potential misclassification 
of glaucoma cases was also a limitation of our data source, 
which relied upon the electronic medical health record. We 
were unable to use a standardized prospectively collected 
data approach to evaluate lenticular opacities, yet our results 
were consistent with results obtained by Chylack et al who 
used LOCIII scores to classify glaucoma.
Another methodological concern with control selection 
among diseases with insidious onset was raised by Garbe 
and colleagues in 1998, where they indicate that serious 
selection bias may occur if the controls do not have the same 
opportunity for diagnosis as the cases.25 Given that there is a 
similar opportunity in the study population to be diagnosed 
and that matching by GP site accounts for the possible differ-
ences in GP referral practice to a specialist, we feel that the 
bias concern is greatly reduced. Additionally, we excluded 
cases from our analysis that did not have matched controls 
for the major confounders measured in the database (age, 
gender, GP, and length of time in the cohort), which resulted 
in fewer cases younger than 50 years in the final analysis. 
Consequently, the final results are less generalizable to a 
younger population of patients with COPD with the trade-off 
of improved adjustment for confounding in the matched sets 
of cases and controls.
We did not observe an association between prescrip-
tions of FSC or other ICS in the previous year and increases 
in odds of incident cataracts or glaucoma in these nested 
  case-control analyses of a large population-based COPD 
cohort of 53,191 patients from the United Kingdom. How-
ever, given the   presence of significant risk factors for cataracts 
and glaucoma in COPD patients, primary care physicians 
should be further sensitized to screening for the presence 
of increased ocular pressure and cataracts prior to initiating 
therapy and   continued monitoring. These data should be 
considered together with results from other observational 
studies and those from randomized clinical studies of longer 
duration in order to obtain a clearer understanding of the 
long-term   benefit to risk profile of ICS-containing products 
in the treatment of COPD, including the risk of cataracts 
and glaucoma.
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